Related Experiment Videos
Experience with the EMIT method of determining anticonvulsant levels in serum
Insights
This study evaluated the EMIT immunoassay for measuring serum phenobarbitone levels in children. Many patients required dosage adjustments based on these crucial drug level determinations.
Area of Science:
- Clinical Chemistry
- Pharmacology
- Immunochemistry
Background:
- Accurate monitoring of serum phenobarbitone levels is essential for effective epilepsy management in children.
- Therapeutic drug monitoring (TDM) guides dosage adjustments to optimize efficacy and minimize toxicity.
Purpose of the Study:
- To report clinical and laboratory experience with the EMIT (Enzyme Multiplied Immunoassay Technique) for serum phenobarbitone determination.
- To assess the utility of a modified manual EMIT method in a routine clinical chemistry setting.
Main Methods:
- A modified manual EMIT immunoassay was employed for serum phenobarbitone level determination.
- Clinical data from 75 pediatric patients undergoing phenobarbitone therapy were analyzed.
Main Results:
- The EMIT method was successfully implemented in a general clinical chemistry laboratory.
- Serum phenobarbitone levels indicated a need for dosage change in 42 out of 75 (56%) children monitored.
Conclusions:
- The modified manual EMIT immunoassay is a practical and effective method for therapeutic drug monitoring of phenobarbitone in pediatric patients.
- Routine monitoring using this assay can identify children requiring phenobarbitone dosage adjustments, improving treatment outcomes.
Abstract:
Clinical and laboratory experience with the EMIT immunoassay method for the determination of serum phenobarbitone levels is reported. A modification of the published laboratory method permitting manual operation in a general clinical chemistry laboratory was used. In 42 of the 75 children monitored, the serum levels of phenobarbitone indicated a change of the prescribed dosage.